

Lumizyme® (alglucosidase alfa) **Medication Precertification Request**

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: 1-866-752-7021 FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857 FAX: 1-844-268-7263

Please indicate: Start of t	reatment, start	date:	<u>/ / / </u>	_ C	ontinuation of therapy,	date of last t	reatment:	<u> </u>		
Precertification Requested	Ву:				Phone:		Fax:			
A. PATIENT INFORMATION										
First Name:			Last Name:							
Address:				Ci	ty:		State:	ZIP:		
Home Phone:		Work	Phone:		C	ell Phone:				
DOB:	Allergies:						E-mail:			
Current Weight:	lbs or	kgs	Height:		inches or	cms				
B. INSURANCE INFORMATI	ON									
Member ID #:	flember ID #:			Does patient have other coverage? ☐ Yes ☐ No						
Group #:			If yes, provide ID#: Carrier Name:							
Insured:			Insured:							
Medicare: ☐ Yes ☐ No If	yes, provide ID #	# :	<u> </u>	Med	icaid: Yes No	If yes, provide	ID #:			
C. PRESCRIBER INFORMAT	TION									
First Name:			Last Name:		(CI	neck one): [☐ M.D. ☐	D.O.		
Address:				Ci	ity:		State:	ZIP:		
Phone:	Fax:		St Lic #:	NI	PI #:	DEA #:	ı	UPIN:		
Provider E-mail:			Office Contact Name:				Phone:			
Specialty (Check one):	ourologist 🗆	Cardiologist					1			
D. DISPENSING PROVIDER										
Place of Administration:	ADMINISTRAT	ON INFORM	IATION		Dispensing Provide	r/Pharmacy:	(Patient sel	lected choice)		
Self-administered	☐ Physician	's Office			'	-	•	,		
Outpatient Infusion Cent	Specialty Pharmacy									
Center Name:				=						
	Phone			_	Name:					
Agency Name:				_	Address:					
Administration code(s) (0	OPT):			_	Phone:					
Address:					TIN:		PIN:			
E. PRODUCT INFORMATION	N									
Request is for: Lumizyme	(alglucosidase	alfa) Dose):		Directions for Use: _					
F. DIAGNOSIS INFORMATION	DN - Please indid	cate primary	ICD code and specify a	iny o	other any other where ap	plicable (*).				
Primary ICD Code:					r ICD Code:	· · · · · · · · · · · · · · · · · · ·				
G. CLINICAL INFORMATION	I - Required clin	ical informati				ests.				
For All Requests (clinical do					'					
☐ Yes ☐ No Is this infusio										
Yes No Has the patient experienced an adverse event with the requested product that has not responded to conventional										
					enhydramine, fluids, othe			ng of infusion rate) or a n, or seizures) during or		
		,		Cloid	reactions, myocardiar i	marction, thro	mboembolisi	n, or seizures) during or		
□Yes□	immediately after an infusion? ☐ Yes ☐ No Does the patient have laboratory confirmed alglucosidase alfa antibodies?									
			-	-			ventions only	available in the		
	☐ Yes ☐ No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?									
☐ Yes ☐					s and/or physical or cog		ent that woul	d impact the safety of		
the infusion therapy AND the patient does not have access to a caregiver? Please provide a description of the behavioral issue or impairment:										
ПYes Г			•		le respiratory, cardiovas	cular. or renal	conditions th	nat may limit the		
T										
member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?										
	→ Please pro	ovide a descr	ription of the condition:		Cardiopulmonary:					
					Respiratory:					
					Renal:					
No. 1. House Stock		D	/!							
☐ Yes ☐ No Is the patient	ulagnosed with	rompe disea	ase (acio alpha-glucosio	uase	: [GAA] deticiency)?					



Lumizyme® (alglucosidase alfa) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: 1-866-752-7021 **FAX:** 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857 FAX: 1-844-268-7263

Patient First Na	ame	Patient Last Name	Patient Phone	Patient DOB									
6. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.													
For Initiation R	equests (clinical documentati	on required for all requests):											
Yes No Was the diagnosis of Pompe disease confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase (GAA) enzyme activity OR by genetic testing?													
For Continuation	on Requests (clinical docume	ntation required for all requests):											
☐ Yes ☐ No	No Is the patient responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, cardiorespiratory function, decrease in left ventricular mass index (LVMI), delay in death)?												
H. ACKNOWLE	EDGEMENT												
Request Com	pleted By (Signature Requir	red):		Date:/	1								
any insurance	company by providing materi	or authorization of coverage of a medica ally false information or conceals materi such person to criminal and civil penaltio	al information for the purpose o	• •									

The plan may request additional information or clarification, if needed, to evaluate requests.